贝伐珠单抗与PD-1免疫疗法联合放疗在NSCLC脑转移患者临床治疗中的应用  

Application of bevacizumab and PD-1 immunotherapy combined with radiotherapy in the clinical treatment of NSCLC patients with brain metastases

作　　者：常虹 方杰 陈坚 Chang Hong;Fang Jie;Chen Jian(Shanghai General Hospital of Chinese People’s Armed Police Force,Shanghai 200052,China;Shanghai Anda Hospital,Shanghai 201204,China)

机构地区：[1]中国人民武装警察部队上海市总队医院,上海200052 [2]上海安达医院,上海201204

出　　处：《首都食品与医药》2025年第4期64-67,共4页Capital Food Medicine

摘　　要：目的探讨非小细胞肺癌(NSCLC)脑转移患者应用贝伐珠单抗+程序性细胞死亡蛋白-1(PD-1)免疫疗法+放疗方案取得的效果。方法纳入2020年1月-2022年12月本院36例NSCLC脑转移患者,根据随机数表法予以分组,予以18例对照组患者化疗+立体定向放疗(SRT),予以18例观察组患者贝伐珠单抗+PD-1免疫疗法+SRT治疗。观察两组治疗12周的近期疗效,比较其治疗前、治疗12周后的肿瘤标志物水平,统计其无进展生存期及总生存期,对比其不良事件发生情况,两组均随访至患者死亡或研究终止。结果观察组患者治疗12周后的近期疗效优于对照组(P<0.05);两组患者治疗12周后血清癌胚抗原(CEA)以及血管内皮生长因子(VEGF)水平均低于治疗前,且观察组比对照组低(P<0.05);随访期间无进展生存期和总生存期比较,观察组均较对照组长(P<0.05);两组各项不良事件对比,均无显著差异(P>0.05)。结论NSCLC脑转移患者临床治疗中,贝伐珠单抗+PD-1免疫疗法+放疗方案的疗效确切,有助于控制肿瘤进展,且具备较高的安全性。Objective To investigate the effect of bevacizumab+programmed cell death protein-1(PD-1)immunotherapy+radiotherapy in patients with brain metastases of non-small cell lung cancer(NSCLC).Methods 36 patients with NSCLC brain metastases in our hospital from January 2020 to December 2022 were included and divided into groups according to random number table method.18 patients in the control group were given chemotherapy+stereotactic radiotherapy(SRT),and 18 patients in the observation group were given bevacizumab+PD-1 immunotherapy+SRT.The short-term efficacy of the two groups after 12 weeks of treatment was observed,the level of tumor markers before and after 12 weeks of treatment was compared,the progression-free survival and overall survival were counted,and the incidence of adverse events was compared.Both groups were followed up until death or study termination.Results The short-term efficacy of observation group was better than control group after 12 weeks of treatment(P<0.05);the serum levels of carcinoembryonic antigen(CEA)and vascular endothelial growth factor(VEGF)in two groups after 12 weeks of treatment were lower than before treatment,and the observation group was lower than the control group(P<0.05).The progression-free survival and overall survival in the observation group were longer than those in the control group(P<0.05).There were no significant differences in adverse events between the two groups(P>0.05).Conclusion In the clinical treatment of patients with NSCLC brain metastases,the regimen of beizumab+PD-1 immunotherapy+radiotherapy is effective,helpful to control tumor progression,and has a high safety.

关 键 词：非小细胞肺癌(NSCLC) 脑转移 贝伐珠单抗 程序性细胞死亡蛋白-1(PD-1) 免疫治疗 立体定向放疗(SRT) 

分 类 号：R734.2[医药卫生—肿瘤]